Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Genomic Tissue Test Predicts Metastasis and Abiraterone Benefit in High-Risk Prostate Cancer

By LabMedica International staff writers
Posted on 27 Oct 2026

Prostate cancer is the most common cancer in men, affecting more than 1 million men worldwide in 2013. More...

Its clinical course varies substantially between patients, complicating efforts to identify those who need intensified treatment and those who may avoid additional toxicity. To help guide these decisions, new findings suggest that a tissue-based molecular test may refine treatment selection in men with high-risk disease.

University College London (UCL, London, UK) researchers evaluated Veracyte’s (South San Francisco, CA, USA) Decipher tissue-based molecular test in men with non-metastatic prostate cancer, assessing whether its molecular score could predict outcomes and treatment benefit. Specifically, the analysis examined whether Decipher could identify which patients would benefit most from adding the hormone therapy abiraterone to standard treatment.

The UCL team examined Decipher scores from two datasets: real-world data from 27,607 men, including 5,956 analyzed for outcomes, and 401 men randomized within the STAMPEDE abiraterone trial. Findings from STAMPEDE, presented at a major cancer conference in Madrid, showed that adding abiraterone to standard treatment for high-risk, localized prostate cancer could halve the risk of death from the disease and slow overall progression.

Across the analysis, higher Decipher scores consistently predicted worse outcomes. For every 0.1 increase in score, the adjusted hazard ratio for distant metastasis was 1.49, while the hazard ratio for prostate cancer death was 1.38. Beyond predicting prognosis, the score also identified which patients without lymph node involvement would benefit from abiraterone in preventing distant spread.

The work involved UCL Cancer Institute and Veracyte, with the findings presented in the context of treatment decisions for very high-risk prostate cancer. The researchers emphasized that further validation in other datasets is needed before the test is used routinely to guide these decisions.

“For men with very high-risk prostate cancer, preventing the cancer from spreading is critical, and understanding who benefits most from additional treatment can make a meaningful difference. Our findings suggest that a genomic test could help personalize treatment: men with high-risk disease but a low Decipher score have low rates of cancer spread and could potentially be spared more intensive treatment, while men with a high score could be prioritized for it,” said Dr. Sarah Howlett, lead researcher at UCL Cancer Institute.

“Showing the same pattern in both a large real-world dataset and a randomized clinical trial strengthens the findings. But further validation in other datasets is needed before the test is used routinely to make these decisions,” added Dr. Howlett.

Related Links
UCL Cancer Institute
Veracyte


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.